Antivirals: Herpes & Influenza
A virus is the ultimate hijacker — it has almost no machinery of its own, using your cells to make copies of itself. So how do you poison the virus without poisoning the cell it hides in? The answer is one of the most elegant tricks in all of pharmacology: a drug that stays harmless everywhere in your body EXCEPT inside a virus-infected cell, where the virus itself unwittingly switches it on.
A patient with a painful outbreak of shingles is given aciclovir, and the drug does something remarkable: as it circulates through the body, it stays completely inert — until it enters a cell infected by the virus. There, the virus's own enzyme activates the drug, turning it into a poison that jams the virus's replication, while every uninfected cell is left untouched. It's a booby-trap the virus springs on itself. That principle of viral self-activation is the key to how we treat herpes viruses — and a lesson in the strange challenge of fighting a hijacker.
The challenge, and the herpes solution
Viruses live inside our cells, so targets are scarce. A virus carries almost no machinery of its own — it hijacks our cells to reproduce — so there are very few virus-specific targets to attack without harming us, and antiviral drugs generally SUPPRESS a virus rather than cure it. Aciclovir solves this beautifully for herpes viruses. It's a prodrug that must be activated in three steps, and the very FIRST step is carried out by an enzyme (thymidine kinase) made only by the herpes virus. So the drug is switched on ONLY inside infected cells; there it becomes a false building block that both blocks the viral DNA polymerase and terminates the growing DNA chain. Its prodrug cousins valaciclovir and famciclovir are simply better-absorbed oral versions. Together they treat the herpes simplex viruses (cold sores, genital herpes, and the dangerous herpes encephalitis) and varicella-zoster (chickenpox and shingles).
A related but more toxic drug, ganciclovir (and its oral form valganciclovir), works the same way against cytomegalovirus (CMV) — a virus that endangers transplant recipients and people with advanced HIV — but it can suppress the bone marrow. For CMV that resists these, foscarnet and cidofovir attack the viral polymerase directly, at the cost of kidney toxicity. The pattern holds: exploit a virus-specific enzyme, and reserve the harsher drugs for the harder infections.
Influenza: blocking escape
Influenza has its own targetable step. To spread, new virus particles must be cut free from the surface of an infected cell by a viral enzyme called neuraminidase. The neuraminidase inhibitors — oseltamivir (Tamiflu) and zanamivir — block that enzyme, so the new viruses stay stuck and can't move on to infect more cells. The catch is timing: they only help if started very early (within about 48 hours of symptoms), and even then they shorten the illness only modestly. A newer drug, baloxavir, blocks a different viral enzyme. (The old M2 blocker amantadine is no longer used for flu because of widespread resistance.) The real headline for influenza, though, is prevention: vaccination remains far more effective than any of these drugs at avoiding the disease in the first place.
- Viruses hijack host cells → few targets; antivirals usually suppress, not cure.
- Aciclovir is activated by VIRAL thymidine kinase → active only in infected cells (selective).
- Aciclovir/valaciclovir treat HSV (cold sores, genital, encephalitis) and VZV (chickenpox, shingles).
- Ganciclovir → CMV (myelosuppression); foscarnet/cidofovir for resistant CMV (nephrotoxic).
- Influenza: neuraminidase inhibitors (oseltamivir) — start within 48h; vaccination is the main defence.
Aciclovir is arguably the most elegant example of selective toxicity in all of pharmacology. It exploits not a structure but an ENZYME the pathogen makes and we don't: the herpes virus's own thymidine kinase performs the first activation step, so the drug is a loaded trap that only detonates inside a cell the virus has already invaded. Uninfected cells never activate it, so it's remarkably safe. This is the same logic as metronidazole (activated only by anaerobes) — a drug switched on by the very organism it's meant to kill.
- Expecting an antiviral to 'cure' herpes. It suppresses outbreaks; the virus stays latent.
- Starting oseltamivir late. It only helps within about 48 hours of flu symptoms.
- Giving antibiotics for a viral cold or flu. Antivirals and antibiotics are different worlds.
- Forgetting ganciclovir's myelosuppression and foscarnet/cidofovir nephrotoxicity.
Why is aciclovir toxic only to virus-infected cells?
- Viruses hijack host cells → antivirals mostly suppress, not cure.
- Aciclovir is activated by viral thymidine kinase → selective; treats HSV & VZV.
- Ganciclovir → CMV (myelosuppression); resistant CMV → foscarnet/cidofovir (nephrotoxic).
- Influenza: neuraminidase inhibitors (oseltamivir) within 48h; vaccination is the main defence.
- Katzung BG. Basic & Clinical Pharmacology — Antiviral Agents (herpes & influenza).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antiviral agents (non-retroviral).
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Antiviral drugs.
- IDSA / CDC guidance — Herpes, CMV & influenza antiviral treatment.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Antiviral drugs.
